


eMed[®] | Empathetic AI[™]

POPULATION HEALTH GLP-1/GIP PROGRAM


GLP-1/GIP medications
are the **BREAKTHROUGH
MEDICATION OF THE
CENTURY** for the
treatment of many
chronic health conditions

50% of the US population qualify under
current FDA indications for GLP-1/GIPs




TYPE 2 DIABETES

Approved: 2017
Stimulates insulin production and
reduces blood sugar leading to
better control and fewer
complications



OBESITY

Approved: 2024
Incretins exert an effect on smooth
muscles of the stomach, delayed
gastric emptying, and an increased
feeling of satiety




KIDNEY DISEASE

Approved: 2025
Reduce the risk of kidney disease
worsening, kidney failure and death due
to cardiovascular disease in adults with
type 2 diabetes and chronic kidney
disease



HEART DISEASE

Approved: 2024
Reduces the risk of major cardiac
events independently of the additional
reduction in risk factors such as
dyslipidemia and atherosclerosis




**OBSTRUCTIVE SLEEP
APNEA**

Approved: 2024
Significantly reduces apneic
episodes and improves sleep
architecture

Future GLP-1/GIP indications will REVOLUTIONIZE POPULATION HEALTH

Future GLP-1/GIP indications




LIVER DISEASE

Under study for reducing liver fat and fibrosis. It stimulates insulin production and reduces blood sugar leading to better control and fewer complications



POLYCYSTIC OVARY SYNDROME (PCOS)

Researchers are evaluating metabolic and hormonal effects, reducing androgens, regulating menstrual cycles and hormones levels



MENOPAUSE

May reduce menopause symptoms, including fatigue, hot flashes, mood swings, weight gain and insulin resistance



ALCOHOL & SUBSTANCE USE

Reduces alcohol cravings and can help addictive behaviors




ALZHEIMER'S DISEASE

Under study to assess if GLP-1/GIP medication can slow cognitive decline in individuals with early-stage Alzheimer's disease

**RISK, COST, DURATION
AND DEMAND**
are the 4 main
GLP-1/GIPs challenges

eMed provides support with:



ACCESS



ACCOUNTABILITY




ADHERENCE



ADDITIONAL COSTS


The program begins
with an **AT-HOME**
PRESCRIBED AND
PROCTORED
eMed GLP-1/GIP
Screening Kit™



Instant access to live care.
No appointments ever.

eMed Empathetic AI™ validates participant's ID and medical history combined with **AI TOOLS** **TO ENABLE THE WORLDS** **EASIEST BIOMETRICS** **CAPTURE**

eMed Empathetic AI™ biometrics




Weight

Advanced **computer vision technology** conducts **real-time analysis** and verification of weight as the participant stands on a scale



Height

Comprehensive **image analysis** processes a **full-body photograph** to accurately determine the participant's height




Blood Pressure

Utilizing advanced computer vision, signal processing, and machine learning algorithms, **PPG signals are extracted and analyzed** to deliver blood pressure readings*

*Pending FDA approval for medical use

At-home blood collection

- Live proctor **guides and certifies** at-home no needle blood collection
- Automated overnight **pick up**



eMed USES 9 CRITICAL TESTS to screen participants:


- HbA1c
- TOTAL CHOLESTEROL
- TRIGLYCERIDES
- LDL
- HDL
- TSH
- ALT/AST (UK)
- BUN
- CREATININE

Indications discovered include:

- Type 2 diabetes
- Hepatitis
- Hypothyroidism/Hyperthyroidism
- Cardiovascular risk factors
- Chronic kidney disease
- Liver dysfunction

eMed Empathetic AI™
CONSOLIDATES
PARTICIPANT LABS,
MEDICAL HISTORY,
AND BIOMETRICS for
review by an
independent clinician

Results delivered from the Lab for clinical
review and aggregated in a summary
report provided to the patient



eMed’s independent
clinicians use
NON-DISCRIMINATORY
ON LABEL GUIDELINES for
qualification

On label inclusion criteria

Morbidity:

Prediabetes
Type 2 diabetes
Dyslipidemia
MASH (NASH)

Hypertension
Stroke
Coronary artery disease
Obstructive sleep apnea

BMI ≥ 30
BMI ≥ 27 + comorbidity:

Diagnostics:


HbA1c, Triglycerides,
Total Cholesterol, LDL,
HDL, ALT

Health Intake
Survey


Verified Weigh-in
AI BMI
Blood Tests

Zepbound approved for weight management, BMI ≥30 (obesity), BMI ≥27 + comorbidities (overweight) ([FDA](#))
Mounjaro approved for type 2 diabetes ([FDA](#))
Wegovy approved for chronic weight management ([FDA](#))
Ozempic approved for diabetes & cardiovascular risk ([FDA](#))
GLP-1s reduce kidney disease risk in diabetes ([Novo Nordisk](#))

QUALIFIED PARTICIPANTS
receive their GLP-1/GIP
medication with
at-home delivery




Qualified Participants
receive medication with
AT-HOME delivery through
PBM's/Manufacturer's
mail-order pharmacies




Safe Transport

Insulated packaging prevents temperature-related degradation of GLP-1/GIP drugs for up to 24 hours.




Proper Titration

Guaranteed inventory ensures continuous access to a participant's prescribed dose.



Increased Adherence

Timely prescription delivery enables uninterrupted adherence to a participant's medication regimen.



Real-Time Tracking


Continuous monitoring to ensure delivery success guarantees chain of custody

Participants complete a weekly, no appointment required, 60 second check-in for **MEDICATION ADHERENCE**


Text Reminder




Virtual Proctor



Verified Weigh-in



Scan Medication




Medications are provided
to **HELP MANAGE SIDE
EFFECTS** with initial
GLP-1/GIP dose delivery

24/7 Side Effect Support



Nausea and Vomiting

- Eat a small meal before taking your dose
- Drink more water and try peppermint tea
- **Zofran** – helps prevent nausea and vomiting



Acid Reflux

- Eat smaller, more frequent meals
- Avoid foods that trigger symptoms
- Avoid excessive alcohol intake
- **Gaviscon** – helps with heartburn and indigestion



Diarrhea

- Drink water and Dioralyte
- Eat easy-to-digest foods like rice, bananas, and plain toast
- **Loperamide** – for relief from diarrhea



Constipation

- Eat high-fibre foods like fruits, vegetables, and whole grains
- Stay active – physical activity supports digestion
- **Senna** – for gentle relief from constipation




Bloating and Gas

- Avoid gas-producing foods and fizzy drinks
- Exercise more frequently
- **Windeze** – reduces bloating and gas

Clinicians review
participants' survey
information and relevant
data **EVERY 30 DAYS** to
prescribe and manage
the medication

Reviewed Data



Medication
Adherence



Weight
Fluctuations



Participant Survey




Side
Effects



Changes in
Medical History

eMed Lifestyle provides support with AI generated diets, exercise guidance and weekly progress reports

eMed Lifestyle



Personalized GLP-1/GIP specific diet recommendations

Instructional Exercise Videos and Educational Content



Private online community groups

Bi-annual screening and blood collection



eMed Empathetic AI™
Population Health
Platform **REDUCES THE
COST OF YOUR
BASELINE GLP-1/GIP
PROGRAM BY 50%**

	*10,000 covered lives	
	Current GLP-1/GIP Cost	eMed Population Health Program
Qualified GLP-1/GIP Population	4,000	4,000
Participants	1,500	1,000
Medical Services, Screenings and Support	\$3.0M	\$2.0M
GLP-1/GIP Medication	\$16.2M	\$7.8M
Total Cost	\$19.2M	\$9.8M


**5 year guaranteed pricing with 12-month
cancellation clause for participating
organizations**

*Example only. Actual pricing based upon specific employer information.


eMed creates a
PARADIGM SHIFT
to this new treatment



FOR UNIONS



FOR FUNDS



FOR MEMBERS



FOR RESULTS



FOR POPULATION HEALTH